$RLYP (Relypsa, Inc.)

$RLYP {{ '2016-07-26T10:34:05+0000' | timeago}} • Announcement

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the BoD of biopharma company $RLYP related to the proposed acquisition of the company by Galenica Group valued at $1.53Bil. Under agreement terms, $RLYP shareholders will receive $32 in cash for each $RLYP share they own.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$PRGO {{ '2018-01-08T12:05:55+0000' | timeago}} • Announcement

$PRGO named Uwe Rohrhoff as CEO, effective Jan. 15, 2018, following the retirement of John Hendrickson. Rohrhoff was the former CEO at Gerresheimer AG. Hendrickson to remain with the company until March 15, 2018 to ensure successful transition.

$PFE {{ '2018-01-04T13:11:11+0000' | timeago}} • Announcement

Arvinas LLC collaborates with $PFE for the discovery and development of drug candidates using Arvinas' PROTAC Platform, a novel technology used to create small molecule therapeutics aimed at degrading disease-causing cellular proteins. Arvinas may receive up to $830MM in upfront and potential development and commercialization milestone payments.

$PFE {{ '2017-12-26T12:25:28+0000' | timeago}} • Announcement

$PFE and $MRK announced that the US FDA has approved STEGLATRO (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets for adults with type 2 diabetes.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$MRK {{ '2017-12-22T16:34:34+0000' | timeago}} • Announcement

$MRK and $PFE announced that the FDA approved STEGLATROTM (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets.

$PFE {{ '2017-12-21T21:14:41+0000' | timeago}} • Announcement

$PFE announced that the US FDA has granted Breakthrough Therapy Designation for avelumab in combination with INLYTA for treatment-naive patients with advanced renal cell carcinoma (RCC). This is the second Breakthrough Therapy Designation granted to avelumab.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$PFE {{ '2017-12-20T12:23:04+0000' | timeago}} • Announcement

The US FDA has approved $PFE's supplemental New Drug Application to expand the indication for BOSULIF  to include adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph CML).

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$PFE {{ '2017-12-18T19:31:58+0000' | timeago}} • Announcement

The BoD of $PFE has increased the quarterly dividend by 6% to $0.34 per share. The first quarter 2018 cash dividend will be payable on March 1, 2018, to shareholders of record on Feb. 2, 2018. The board also authorized a new $10Bil share repurchase program, in addition to the $6.4Bil remaining under the current authorization.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

$AGN {{ '2017-12-12T19:58:45+0000' | timeago}} • Announcement

$AGN gets FDA clearance for the CoolSculpting, a treatment to improve the appearance of lax tissue in double chin. Allergan got this CoolSculpting technology by acquiring Zeltiq Aesthetics in Feb. 2017 for $2.4Bil. Allergan added that in an 18-week study, 77% of patients showed improved appearance in their lax tissue.

$AGN {{ '2017-12-12T19:07:05+0000' | timeago}} • Announcement

$AGN enters into a buyout deal with $RPRX through a cash tender offer of $0.67 per share, representing a 43% premium of Repros Therapeutics’ Dec. 11th closing price ($0.47). Allergan's subsidiary will acquire Repros, which focuses on developing the drugs for male and female reproductive disorders. The deal is expected to close in 1Q18.

$LLY {{ '2017-12-11T17:36:13+0000' | timeago}} • Announcement

FDA accepts to review $LLY's Galcanezumab, an injectionable drug for the treatment of migraine. Rivals $NVS and $AMGN already filed their migraine drug with FDA in July 2017, while $TEVA is also expected to join the race. Lilly's pain portfolio also includes Tanezumab, developed in partnership with $PFE, for the treatment of osteoarthritis.

$JCI {{ '2017-12-11T16:43:09+0000' | timeago}} • Announcement

$JCI's BoD appointed John Young to serve as a director. Young is currently group president of $PFE Essential Health. Effective Jan. 1, 2018, he will become group president of Pfizer Innovative Health, which comprises six business groups focused on improving health through innovative products covering every stage of life.

$AGN {{ '2017-12-05T18:08:04+0000' | timeago}} • Announcement

Revance Therapeutics reported positive data for RT002, an injectable drug which would treat glabellar or frown lines. With positive results from the two Phase 3 trials, $AGN's rival plans to complete the third Phase 3 trial in 2H18 and file for FDA approval in 1H19, and introduce the competitive drug for Allergan's Botox in the U.S. in 2020.

$PFE {{ '2017-12-01T11:52:44+0000' | timeago}} • Announcement

$PFE enters into agreement with Basilea Pharmaceutica Ltd to develop and commercialize CRESEMBA in China and Asia Pacific region. CRESEMBA is a novel antifungal medicine for the treatment of adult patients with diagnosed invasive aspergillosis and mucormycosis.

Recent Transcripts

IMUC (ImmunoCellular Therapeutics, Ltd.)
Tuesday, November 21 2017 - 10:00pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
PRGO (Perrigo Company Public Limited Company)
Thursday, November 9 2017 - 1:00pm
OPK (Opko Health, Inc.)
Wednesday, November 8 2017 - 9:30pm
TARO (Taro Pharmaceutical Industries Ltd.)
Wednesday, November 8 2017 - 1:00pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
USPH (US Physical Therapy Inc.)
Thursday, November 2 2017 - 2:30pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, November 2 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
PFE (Pfizer Inc.)
Tuesday, October 31 2017 - 2:00pm
WCG (WellCare Health Plans, Inc.)
Tuesday, October 31 2017 - 1:30pm
IMUC (ImmunoCellular Therapeutics, Ltd.)
Wednesday, August 23 2017 - 9:00pm
HEB (Hemispherx Biopharma, Inc.)
Tuesday, August 15 2017 - 5:00pm
PRGO (Perrigo Company Public Limited Company)
Thursday, August 10 2017 - 12:00pm
OPK (Opko Health, Inc.)
Tuesday, August 8 2017 - 8:30pm
WCG (WellCare Health Plans, Inc.)
Friday, August 4 2017 - 1:00pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
USPH (US Physical Therapy Inc.)
Thursday, August 3 2017 - 2:30pm
SYN (Synthetic Biologics Inc.)
Thursday, August 3 2017 - 12:30pm

AlphaGraphics you may like